Efficacy of NK 001 [etanercept] for the prevention of Alzheimer's related cognitive impairment in patients undergoing coronary artery bypass surgery.

Trial Profile

Efficacy of NK 001 [etanercept] for the prevention of Alzheimer's related cognitive impairment in patients undergoing coronary artery bypass surgery.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2011

At a glance

  • Drugs Etanercept (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Neurokine Pharmaceuticals
  • Most Recent Events

    • 02 May 2011 Neurokine expects to obtain approval for this trial by August 2011.
    • 03 Feb 2011 Neurokine expect to submit their phase II protocol, for approval by the European authorities, by the end of March 2011, according to their media release.
    • 03 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top